Mersana Therapeutics Inc Share Price MRSN

$29.1

▲

0.06

(0.21%)

Last updated on January 5, 2026 at 12:00 am IST

$₹

This instrument is not available for trading on the INDmoney app on 5 Jan 2026

Check the interactive Mersana Therapeutics Inc Stock chart to analyse performance

Mersana Therapeutics Inc Key Stats

Check Mersana Therapeutics Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$29.04
Open	$28.9
Market Capitalization	$145.2M
Today's Volume	$712.5K
Revenue TTM	$33.2M
EBITDA	$-66.3M
Earnings Per Share (EPS)	$-13.95
Profit Margin	-211.22%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-505.14%

Global Institutional Holdings in Mersana Therapeutics Inc

Name
Holdings %
Name
Holdings %
Nextech Invest, Ltd.
9.67%
Bain Capital Life Sciences Investors, LLC
6.94%
Vanguard Group Inc
6.71%
BlackRock Inc
6.67%
Schonfeld Strategic Advisors LLC
6.10%
AQR Capital Management LLC
4.12%

Analyst Recommendation on Mersana Therapeutics Inc Stock

Rating

Trend

Buy

80%Buy

20%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Mersana Therapeutics Inc(by analysts ranked 0 to 5 stars)

Mersana Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$42.1M	↑ 297.61%
Net Income	$-28.2M	↓ 56.1%
Net Profit Margin	-66.97%	↑ 539.57%

	FY20	Y/Y Change
Revenue	$828.0K	↓ 98.03%
Net Income	$-88.0M	↑ 212.13%
Net Profit Margin	-10.6K%	↓ 10566.48%

	FY21	Y/Y Change
Revenue	$43.0K	↓ 94.81%
Net Income	$-170.1M	↑ 93.15%
Net Profit Margin	-395.5K%	↓ 384854.92%

	FY22	Y/Y Change
Revenue	$26.6M	↑ 61716.28%
Net Income	$-204.2M	↑ 20.08%
Net Profit Margin	-768.26%	↑ 394720.11%

	FY23	Y/Y Change
Revenue	$36.9M	↑ 38.65%
Net Income	$-171.7M	↓ 15.94%
Net Profit Margin	-465.8%	↑ 302.46%

	FY24	Y/Y Change
Revenue	$40.5M	↑ 9.88%
Net Income	$-69.2M	↓ 59.69%
Net Profit Margin	-170.86%	↑ 294.94%

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

	Q2 FY24	Q/Q Change
Revenue	$2.3M	↓ 75.2%
Net Income	$-24.3M	↑ 25.7%
Net Profit Margin	-1.1K%	↓ 849.52%

	Q3 FY24	Q/Q Change
Revenue	$12.6M	↑ 449.41%
Net Income	$-11.5M	↓ 52.61%
Net Profit Margin	-91.29%	↑ 967.06%

	Q4 FY24	Q/Q Change
Revenue	$16.4M	↑ 29.87%
Net Income	$-14.1M	↑ 22.75%
Net Profit Margin	-86.28%	↑ 5.01%

	Q1 FY25	Q/Q Change
Revenue	$2.8M	↓ 83.17%
Net Income	$-24.1M	↑ 70.88%
Net Profit Margin	-875.93%	↓ 789.65%

	Q2 FY25	Q/Q Change
Revenue	$3.1M	↑ 10.97%
Net Income	$-24.3M	↑ 0.72%
Net Profit Margin	-795.03%	↑ 80.9%

	Q3 FY25	Q/Q Change
Revenue	$11.0M	↑ 260.24%
Net Income	$-7.5M	↓ 68.95%
Net Profit Margin	-68.53%	↑ 726.5%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$42.1M	↑ 297.61%

	FY20	Y/Y Change
Profit	$-66.2M	↓ 257.18%

	FY21	Y/Y Change
Profit	$43.0K	↓ 100.06%

	FY22	Y/Y Change
Profit	$26.6M	↑ 61716.28%

	FY23	Y/Y Change
Profit	$36.9M	↑ 38.65%

	FY24	Y/Y Change
Profit	$40.5M	↑ 9.88%

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

	Q2 FY24	Q/Q Change
Profit	$2.3M	↓ 75.2%

	Q3 FY24	Q/Q Change
Profit	$12.6M	↑ 449.41%

	Q4 FY24	Q/Q Change
Profit	$16.4M	↑ 29.87%

	Q1 FY25	Q/Q Change
Profit	$2.8M	↓ 83.17%

	Q2 FY25	Q/Q Change
Profit	$2.8M	↑ 0.54%

	Q3 FY25	Q/Q Change
Profit	$11.0M	↑ 297.58%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-67.7M	↑ 22.69%
Investing Cash Flow	$-27.3M	↓ 131.3%
Financing Cash Flow	$97.7M	↑ 9082.71%

	FY20	Y/Y Change
Operating Cash Flow	$-74.7M	↑ 10.26%
Investing Cash Flow	$37.0M	↓ 235.66%
Financing Cash Flow	$230.4M	↑ 135.83%

	FY21	Y/Y Change
Operating Cash Flow	$-140.0M	↑ 87.41%
Investing Cash Flow	$-648.0K	↓ 101.75%
Financing Cash Flow	$63.6M	↓ 72.38%

	FY22	Y/Y Change
Operating Cash Flow	$-49.4M	↓ 64.74%
Investing Cash Flow	$-152.7M	↑ 23467.28%
Financing Cash Flow	$153.0M	↑ 140.42%

	FY23	Y/Y Change
Operating Cash Flow	$-168.9M	↑ 242.12%
Investing Cash Flow	$119.9M	↓ 178.5%
Financing Cash Flow	$94.7M	↓ 38.13%

	FY24	Y/Y Change
Operating Cash Flow	$-82.3M	↓ 51.24%
Investing Cash Flow	$11.4M	↓ 90.46%
Financing Cash Flow	$4.1M	↓ 95.68%

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-21.9M	↓ 33.08%
Investing Cash Flow	$5.5M	↓ 107.6%
Financing Cash Flow	$153.0K	↓ 97.38%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-8.6M	↓ 60.75%
Investing Cash Flow	$28.5M	↑ 416.32%
Financing Cash Flow	$-23.0K	↓ 115.03%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-19.3M	↑ 124.45%
Investing Cash Flow	$50.0M	↑ 75.62%
Financing Cash Flow	$-1.9M	↑ 8017.39%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-29.3M	↑ 52.33%
Investing Cash Flow	$27.0M	↓ 46.0%
Financing Cash Flow	$-3.1M	↑ 68.02%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-22.6M	↓ 22.93%
Investing Cash Flow	$395.0K	↓ 98.54%
Financing Cash Flow	$-3.1M	↓ 0.92%

	Q3 FY25	Q/Q Change
Operating Cash Flow	$-3.2M	↓ 85.88%
Investing Cash Flow	$372.0K	↓ 5.82%
Financing Cash Flow	$-17.8M	↑ 471.46%

About Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Organization	Mersana Therapeutics Inc
Employees	102
CEO	Dr. Martin H. Huber M.D.
Industry	Health Technology

Key Management of Mersana Therapeutics Inc

Name	Title
Dr. Martin H. Huber M.D.	President, CEO & Director
Mr. Brian C. DeSchuytner	Senior VP, CFO & COO
Dr. Timothy B. Lowinger Ph.D.	Senior VP and Chief Science & Technology Officer
Ms. Alejandra Veronica Carvajal J.D.	Senior VP, Secretary & Chief Legal Officer
Dr. Mohan Bala Ph.D.	Senior VP & Chief Development Officer
Mr. Mikhail Papisov Ph.D.	Co-Founder
Mr. Ashish Mandelia	VP & Chief Accounting Officer
Mr. Chuck Miller	Senior Vice President of Regulatory Affairs

Important FAQs about investing in MRSN Stock from India :

What is Mersana Therapeutics Inc share price today?

Mersana Therapeutics Inc share price today is $29.10 as on January 5, 2026 at 12:00 am IST at the close of the market. Mersana Therapeutics Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Mersana Therapeutics Inc share?

Mersana Therapeutics Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Mersana Therapeutics Inc stock price today i.e. January 5, 2026 at 12:00 am IST is closed at $29.10, lower by 19.72% versus the 52 week high.

How to invest in Mersana Therapeutics Inc Stock (MRSN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Mersana Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mersana Therapeutics Inc Shares that will get you 0.0515 shares as per Mersana Therapeutics Inc share price of $29.10 per share as on January 5, 2026 at 12:00 am IST.

What is the minimum amount required to buy Mersana Therapeutics Inc Stock (MRSN) from India?

Indian investors can start investing in Mersana Therapeutics Inc (MRSN) shares with as little as ₹94.3006 or $1 (as of June 28, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹943.01 in Mersana Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on June 28, 2026). Based on Mersana Therapeutics Inc share’s latest price of $29.10 as on January 5, 2026 at 12:00 am IST, you will get 0.3436 shares of Mersana Therapeutics Inc. Learn more about fractional shares .

What are the returns that Mersana Therapeutics Inc has given to Indian investors in the last 5 years?

Mersana Therapeutics Inc stock has given 0.0% share price returns and 26.95% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Simplify VettaFi Private Credit Strategy ETF
$19.21
+1.05%
Generation Income Properties Inc. Common Stock
$0.17
-5.56%
Alger 35 ETF
$39.03
-1.54%
Chart Industries, Inc.
$208.50
-0.16%
VistaShares Electrification Supercycle ETF
$29.41
-3.51%
Amesite Inc. Common Stock
$1.09
+0.93%
FIREFLY AUTOMATIX INC
$0.00
+0.0%
DocuSign, Inc. Common Stock
$45.21
+6.48%
Marti Technologies, Inc.
$1.52
-6.75%

Explore all